Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NNMT | P40261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23650005 | 1.00 | TDP1 (0.58) | TDP1POLBNNMTMEN1USP2 | |
| SCHEMBL29153901 | 0.87 | POLB (0.46) | TDP1POLBNNMTMEN1KMT2A | |
| SCHEMBL23667574 | 0.87 | POLB (0.46) | TDP1POLBNNMTMEN1KMT2A | |
| SCHEMBL9649585 | 0.85 | TDP1 (0.64) | TDP1POLBNNMTMEN1USP2 | |
| SCHEMBL29774201 | 0.84 | TDP1 (0.68) | TDP1POLBNNMTMEN1USP2 | |
| SCHEMBL7901086 | 0.84 | TDP1 (0.68) | TDP1POLBNNMTMEN1USP2 | |
| SCHEMBL23649522 | 0.74 | TDP1 (0.58) | TDP1POLBNNMTMEN1USP2 | |
| SCHEMBL23649520 | 0.74 | TDP1 (0.58) | TDP1POLBNNMTMEN1USP2 | |
| SCHEMBL838850 | 0.74 | NNMT (0.71) | TDP1POLBNNMTMEN1USP2 | |
| SCHEMBL7540568 | 0.74 | TDP1 (0.68) | TDP1POLBNNMTMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240199648-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-06-20 | — | — | US | disclosed |
| EP-4370523-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230112729-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-04-13 | — | — | US | disclosed |
| WO-2023288254-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288264-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2021146370-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534441-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | TDP1 856/4885POLB 3082/4885NNMT 1506/4885 |
| US-20230112729-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | TDP1 756/4885POLB 2761/4885NNMT 1397/4885 |
| US-20240199648-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | TDP1 756/4885POLB 2761/4885NNMT 1397/4885 |
| US-20230140954-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | TDP1 856/4885POLB 3082/4885NNMT 1506/4885 |
| US-12042495-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | TDP1 856/4885POLB 3082/4885NNMT 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.